Ładuje się......
Selpercatinib: First Approval
Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA f...
Zapisane w:
| Wydane w: | Drugs |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Springer International Publishing
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7716849/ https://ncbi.nlm.nih.gov/pubmed/32557397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01343-7 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|